Raloxifene Hydrochloride

[{"orgOrder":0,"company":"Gyeonggido Business and Science Accelerator","sponsor":"CINECA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EU and South Korean Research Organisations Sign an Agreement to Work Together on the Development of a Covid-19 Treatment Using Raloxifene","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid-19 Patients treated at Home and in Medical Facilities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"AmyriAD","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer\u2019s Disease Treatment, AD101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AmyriAD","sponsor":"Societal CDMO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer's Disease Treatment, AD101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Domp\u00e9's AI Platform for Drug Design","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

32 Suppliers, 17 USDMF, 9 CEP/COS, 6 JDMF, 8 EU WC, 7 KDMF, 13 NDC API, 22 Listed Suppliers

DEVELOPMENTS

5 Drug(s) in Development

5 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

24 Suppliers

24 Suppliers

DOSSIERs // Finished Dosage Forms

59 Dossiers, 10 FDA Orange Book, 30 Europe, 4 Canada, 8 Australia, 3 South Africa, 4 Listed Dossiers

RELATED EXCIPIENT COMPANIES

Suppliers, 37 Kerry, 26 BASF, 17 Roquette, 17 SPI Pharma, 15 Microlex e.U, 13 Seppic, 12 Gangwal Chemicals, 10 Corel Pharma Chem, 10 Sigachi Industries, 10 Gangwal Healthcare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 7 Boai NKY Pharmaceuticals Ltd, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 6 Nanjing Well Pharmaceutical, 6 Lonza Capsugel, 5 DFE Pharma, 5 Ideal Cures Pvt Ltd, 5 Actylis, 4 Pharmatrans-Sanaq, 3 Ingredion Pharma Solutions, 3 Ulanqab Kema New Material, 3 Kima Chemical, 3 Prachin Chemical, 2 Alcedo Pharmachem, 2 Nanjing Bold Chemical, 2 Seqens, 2 Finar, 2 Nomisma Healthcare, 2 The Dow Chemical Company, 2 Vasa Pharmachem, 2 Jai Radhe Sales, 2 Clariant, 2 DKSH, 1 Chynops Pharma, 1 Pfanstiehl, 1 Minakem, 1 Avesta Pharma, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Aeon Procare, 1 ACG Worldwide, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Qualicaps, 1 Shanghai Welltone Material Technology Co., Ltd, 1 NEWEDGE Overseas, 1 Rochem International Inc

EXCIPIENTS BY APPLICATIONS

84 Fillers, Diluents & Binders, 44 Coating Systems & Additives, 43 Direct Compression, 30 Solubilizers, 28 Controlled & Modified Release, 27 Thickeners and Stabilizers, 26 Disintegrants & Superdisintegrants, 25 Granulation, 22 Lubricants & Glidants, 20 Chewable & Orodispersible Aids, 18 Parenteral, 17 Co-Processed Excipients, 17 Topical, 15 Taste Masking, 13 Film Formers & Plasticizers, 7 API Stability Enhancers, 7 Emulsifying Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 4 Rheology Modifiers, 2 Coloring Agents

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 26 Finished Drug Prices

MARKET PLACE

3 APIs

3 APIs

PATENTS

6 Health Canada Patents

6 Health Canada Patents

ANALYTICAL SOLUTION(s)

3 BioAnalytical Methods, 2 EDQM Standards, 2 USP Standards, 2 Other Ref. Standards

DIGITAL CONTENT

2 Data Compilation & Company Tracker #PharmaFlow, 28 News

All Data

Developments

Filters

FILTER:

Company

Sponsor

Country

Therapeutic Area

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Dompe Farmaceutici

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Italy

Virtual Booth

Digital Content

Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé's AI Platform for Drug Design

Details:

Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.

Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 26, 2022

ASK
US

Upload
your Pipeline Activity

AmyriAD

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

U.S.A

Virtual Booth

Digital Content

Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer's Disease Treatment, AD101

Details:

AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.

Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Neurology Product Name: AD101

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Societal CDMO

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

ASK
US

Upload
your Pipeline Activity

Societal CDMO

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

U.S.A

Virtual Booth

Digital Content

Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer’s Disease Treatment, AD101

Details:

Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).

Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Neurology Product Name: AD101

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: AmyriAD

Deal Size: $1.0 million Upfront Cash: Undisclosed

Deal Type: Agreement June 01, 2022

ASK
US

Upload
your Pipeline Activity

Gyeonggido Business and Science Accelerator

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Country

Virtual Booth

Digital Content

EU and South Korean Research Organisations Sign an Agreement to Work Together on the Development of a Covid-19 Treatment Using Raloxifene

Details:

This agreement covers the exchange of clinical and nonclinical trial information related to COVID-19 treatment using the repurposed Raloxifene molecule developed by five research organisations from the EU and South Korea.

Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: CINECA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 18, 2020

ASK
US

Upload
your Pipeline Activity

Dompe Farmaceutici

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Italy

Virtual Booth

Digital Content

EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid-19 Patients treated at Home and in Medical Facilities

Details:

A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate4Cov’s guidelines.

Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2020

ASK
US

Upload
your Pipeline Activity

Find Clinical Drug Pipeline Developments & Deals for Raloxifene Hydrochloride